Diplomat Pharmacy (DPLO) Misses Q1 EPS by 2c, Beats on Revenues

Diplomat Pharmacy (NYSE: DPLO) reported Q1 EPS of $0.20, $0.02 worse than the analyst estimate of $0.22. Revenue for the quarter came in at $1.34 billion versus the consensus estimate of $1.29 billion.

First Quarter 2018 Highlights include:

• Revenue of $1,342 million, compared to $1,079 million, an increase of 24%
  • Specialty segment revenue of $1,153 million, compared to $1,079 million
  • PBM segment revenue of $191 million, which was not part of the business in the prior year period
• Specialty segment total prescriptions dispensed of 223,000, compared to 220,000
• PBM segment total volume, adjusted to 30-day equivalent, of 2,181,000
• Gross margin of 8.2% versus 7.9%
  • Specialty segment gross margin of 8.1% versus 7.9%
  • PBM segment gross margin of 9.2%
• EPS of $(0.01) per diluted common share versus $0.06
  • Adjusted EPS of $0.20 versus $0.19
• Adjusted EBITDA of $39.6 million, compared to $26.8 million
  • Adjusted EBITDA margin of 3.0% versus 2.5%
• Net cash provided by operating activities was $48.6 million, compared to $44.3 million
• Net debt, including contingent consideration, reduced to $601.5 million, from $648.7 million at December 31, 2017

For earnings history and earnings-related data on Diplomat Pharmacy (DPLO) click here.

You May Also Be Interested In

• The tech crown switches hands: Apple dethrones Nvidia as $4 trillion king
• Abbott (ABT) Tops Q2 EPS by 3c; offers guidance
• Travelers (TRV) Tops Q2 EPS by $4.92